Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRB 796 BS in Rheumatoid Arthritis
NCT02214888Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2003
- Primary completion
- Jan 2004
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of doramapimod in rheumatoid arthritis (RA) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: American College of Rheumatology 20 Response at 12 weeks. Started May 2003; status: terminated.
02
Drugs
doramapimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02214888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02214888.